A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
Public ClinicalTrials.gov record NCT06907290. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection. The comparator in this study will be 24-weeks of delayed treatment. During the 24-weeks of delayed treatment, participants will complete the same visits and assessments as those randomized to initiate brelovitug immediately. At the completion of 24-week delayed treatment period, all participants will start treatment with brelovitug.
Study identification
- NCT ID
- NCT06907290
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2025
- Primary completion
- Apr 30, 2029
- Completion
- Aug 31, 2029
- Last update posted
- Mar 1, 2026
2025 – 2029
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 247 Garden Grove | Garden Grove | California | 92840 | — |
| 242 Huntington Beach | Huntington Beach | California | 92647 | — |
| 252 Long Beach | Long Beach | California | 90805 | — |
| 244 Los Angeles | Los Angeles | California | 90033 | — |
| 250 Miami | Miami | Florida | 33166 | — |
| 251, Illinois | Chicago | Illinois | 60612 | — |
| 248 Lowa | Cities in Iowa | Iowa | 52242 | — |
| 254 Baltimore | Baltimore | Maryland | 21287 | — |
| 241, Massachusetts | Boston | Massachusetts | 02114 | — |
| 245 New York | New York | New York | 10007 | — |
| 256 New York | New York | New York | 10065 | — |
| 253 New York | New York | New York | 10075 | — |
| 255 New York | New York | New York | 10075 | — |
| 257 Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| 249 San Antonio | San Antonio | Texas | 78215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06907290, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 1, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06907290 live on ClinicalTrials.gov.